Joseph P. Lyssikatos - 01 May 2025 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
01 May 2025
Net transactions value
-$150,391
Form type
4
Filing time
05 May 2025, 18:43:44 UTC
Previous filing
23 Apr 2025
Next filing
21 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER /s/ Ben Hohl, by power of attorney 05 May 2025 0001967150

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Sale $100,966 -5,030 -0.5% $20.07 992,658 01 May 2025 See footnote F1, F2
transaction ELVN Common Stock Sale $49,424 -2,470 -0.25% $20.01 990,188 02 May 2025 See footnote F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $20.00 to $20.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $20.00 to $20.045. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.